- By ICR Secretariat
- Posted Thursday, July 21, 2022
Roche’s combination breast cancer treatment delivers positive results
https://www.pharmatimes.com/news/roches_combination_breast_cancer_treatment_delivers_positive_results_1452295
Roche, the Breast International Group, Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation have announced updated data from the phase 3 APHINITY study into HER2-positive early breast cancer.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- NICE recommendation expands patient eligibility for AbbVie’s Ozurdex 18/08/2022 03:38 PM
- Amgen’s low tax rates draw attention of top Democratic senator 18/08/2022 03:23 PM
- 2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again 18/08/2022 03:16 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org